Healthcare

https://techpapersworld.com/wp-content/uploads/2025/01/TNF-Pharmaceuticals-Launches-Study-Series--1280x720.jpg

HealthcareTNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it has initiated the first in a series of studies to evaluate the impact of its novel oral TNF-alpha (TNF-α) inhibitor drug, isomyosamine, in preserving lean muscle mass during and after GLP-1 treatment for weight loss and chronic weight management. “The body of evidence for the GLP-1 drug...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2025/01/Psychedelic-Drug-Therapy--1280x720.jpg

HealthcarePsychedelic Drug Therapy May Address Mental Health Concerns in People with Cancer and Addiction

One or two doses of psilocybin, a compound found in psychedelic mushrooms, may improve the mental health of cancer patients when accompanied by psychotherapy, a new report suggests. A second new study found that treatment with psilocybin resulted in lasting, positive personality changes in patients with alcohol use disorder. The first report’s findings were published online Oct. 7 in the journal Nature Mental Health, and the second published online Jan. 1 in a special edition of The American Journal of Psychiatry focused on psilocybin...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2025/01/A-speckle-of-hope-for-cancer-1280x720.jpg

HealthcareA speckle of hope for cancer patients

Fighting cancer can seem like a deadly game of chance. While some patients may respond well to certain treatments, others might not be as fortunate. Doctors and scientists have long struggled to explain why. Now, Cold Spring Harbor Laboratory (CSHL) Assistant Professor Katherine Alexander and University of Pennsylvania Professor Shelley Berger have found a possible source of this variability in clear cell renal cell carcinoma (ccRCC)—the most common kidney cancer diagnosed in adults. CSHL Assistant Professor Katherine Alexander and colleagues...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/12/Ping-An-Health-Supported-the-1280x720.jpg

HealthcarePing An Health Supported the Official Release of the “Group Standards for Remote and Internet-Based Family Doctor Healthcare Services”

With Ping An Healthcare and Technology Company Limited‘s (“Ping An Good Doctor“, “Ping An Health”, or “the Company”, Stock Code: 1833.HK) strategic support, and guidance from the General Practice Development Research Center of Peking University Health Science Center, The Chinese Aging Well Association and its Family Doctor Branch, the “Group Standards for Remote and Internet-Based Family Doctor Healthcare Services” (the “Group Standards”) were unveiled at a conference in Beijing. The meeting announced the implementation of the year-long...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/12/PQE-Group-Joins-Project-COMFORT-to-Advance-1280x720.jpg

HealthcarePQE Group Joins Project-COMFORT to Advance Patient-Centric Blood Collection and Diagnostics

PQE Group, a global consulting firm specializing in Life Sciences, is proud to contribute its expertise as a strategic partner in the Project-COMFORT consortium. This innovative public-private partnership, funded by Horizon Europe and supported by the Innovative Health Initiative Joint Undertaking (IHI JU), officially launched in November 2024, marking a transformative shift in blood collection and diagnostics. The ambitious 42-month project brings together 51 organizations from a broad spectrum of sectors, including academia, research institutions,...

by business wire

https://techpapersworld.com/wp-content/uploads/2024/12/Meaningful-Insights-Biotech-Analytics-1280x720.jpg

HealthcareMeaningful Insights Biotech Analytics (MiBA) and Guardant Health Announce Strategic Partnership to Optimize Use of Biomarker Testing and Data Analytics to Improve Cancer Care

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Meaningful Insights Biotech Analytics (MiBA), an innovative healthcare technology company, today announced a unique partnership aimed at optimizing the use of biomarker testing and data analytics to advance precision medicine in patient care throughout the MiBA Network. “This collaboration with Guardant Health is an innovative approach to precision oncology. By leveraging our technology and data insights, we can enhance understanding and accessibility of genomic...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/12/Fangzhou-Inc.-and-Bristol-Myers-1280x720.jpg

HealthcareFangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare

Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a pioneer in Internet healthcare solutions, announced a strategic alliance with Bristol Myers Squibb (“BMS”) China on December 16th. The partnership was officially formalized with the signing of a collaboration agreement by Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou, and Mr. Wen Yizhong, the head of the Innovative Medicines Division at BMS China and General Manager for BMS Hong Kong. This strategic alliance aims to drive innovation in Internet healthcare...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/12/BioArctic-announces-global-license-agreement-1280x720.jpg

HealthcareBioArctic announces global license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-amyloid-beta antibody program

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol Myers Squibb (NYSE: BMY) for BioArctic’s PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program, including BAN1503 and BAN2803, whereof the latter includes BioArctic’s BrainTransporter™ technology. As part of the agreement, BioArctic will receive a USD 100 million upfront payment and up to USD 1.25 billion in milestone payments. BioArctic is also entitled to tiered low double-digit royalties on global product sales. Under the agreement, Bristol Myers Squibb will become...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/12/Foothill-Regional-Medical-Center-1280x720.jpg

HealthcareFoothill Regional Medical Center Infection Control Expert Receives Top National Honor

Shahbaz Salehi, MPH, MSHIA, director, infection control, at Foothill Regional Medical Center, has been named the 2024 Educator of the Year by Infection Control Today, a national leader in infection control. Orange County’s Shahbaz Salehi Named Infection Control Today’s 2024 Educator of the Year Infection Control Today 2024 Educator of the Year, Shahbaz Salehi, Foothill Regional Medical Center “The 2024 Infection Control Today Educator of the Year award recognizes an individual who has demonstrated exceptional passion and dedication to educating others, empowering...

by PRNewswire

https://techpapersworld.com/wp-content/uploads/2024/12/IDEAYA-Announces-Development--1280x720.jpg

HealthcareIDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the development candidate nomination of IDE251, a potential first-in-class KAT6/7 dual inhibitor. “We are pleased to announce the nomination of IDE251 as our third development candidate this quarter and 8th development candidate in our precision medicine oncology pipeline. IDE251 has a potential first-in-class product profile and selectively inhibits two epigenetic modulators, KAT6 and KAT7, and based...

Older Posts